NCT03409432 2025-07-25Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell LymphomaOhio State University Comprehensive Cancer CenterPhase 2 Completed26 enrolled